Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,399 shares, an increase of 329.1% from the April 30th total of 326 shares. Based on an average trading volume of 1,818 shares, the days-to-cover ratio is currently 0.8 days.
Clinuvel Pharmaceuticals Stock Up 1.8%
Shares of OTCMKTS CLVLY opened at $6.68 on Friday. Clinuvel Pharmaceuticals has a 52 week low of $5.98 and a 52 week high of $9.00. The firm’s fifty day moving average is $6.68 and its 200 day moving average is $7.45.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Further Reading
- Five stocks we like better than Clinuvel Pharmaceuticals
- MarketBeat Week in Review – 05/25 – 05/29
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
